Olaparib continues to show positive results in advanced ovarian cancer - 7 year data from parp Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Prof Paul DiSilvestro, speaks to ecancer about his Phase III SOLO1/GOG-3004 trial which studied the overall survival at 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation who received maintenance olaparib. nnPatients who were in response to first-line platinum-based chemotherapy received maintenance olaparib tablets 300 mg bid or pbo for up to 2 years or until progression. A descriptive analysis of OS, a secondary endpoint, was performed 7y after the l
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)